Login / Signup

The impact of copay assistance on patient out-of-pocket costs and treatment rates with ALK inhibitors.

Arpamas SeetasithWilliam WongJenny TseChakkarin Burudpakdee
Published in: Journal of medical economics (2019)
Copay assistance reduced the patient cost burden for ALKi's and was associated with patients picking up their ALKi prescriptions, beginning ALKi treatment sooner, and remaining on treatment.
Keyphrases
  • end stage renal disease
  • chronic kidney disease
  • ejection fraction
  • patient reported outcomes
  • epidermal growth factor receptor